I've been watching the cannabis stock space pretty closely, and there's a wild contrast playing out right now between two major players that's worth highlighting.

Canopy Growth used to be the king of this sector - back in 2019 and 2021 it was worth over $15 billion. Today? Market cap has cratered to under $400 million, and the stock is down over 40% in the past year. Yeah, they're showing some improvement on paper - Q3 revenue hit $90.4 million up 5% year-over-year, and they cut their net loss by nearly half. But here's the catch: they haven't had a profitable quarter since mid-2021. Plus, they've been issuing massive amounts of new shares to stay afloat, diluting existing shareholders by 142% over the past year alone.

Now compare that to Green Thumb Industries. This is a Chicago-based operation that's actually been printing profits - on track for their sixth straight year of positive earnings. They've got 108 dispensaries and 20 manufacturing facilities across 14 states, operating lean with a debt-to-equity ratio of just 0.28 compared to Canopy's 0.44. In Q3, they reported $292 million in revenue up 1.6% year-over-year with $0.10 earnings per share.

What makes this even more interesting is the Schedule I rescheduling angle. Right now, cannabis companies are getting hammered on taxes because of Schedule I classification - one survey found U.S. cannabis operators paid an extra $2.3 billion in taxes last year just because of that. If reclassification happens in the next couple years as expected, a healthy cannabis stock operator like Green Thumb becomes significantly more profitable without changing anything operationally. They'd suddenly have access to standard business deductions that competitors can't touch.

There's also a potential listing benefit - if rescheduling happens, Green Thumb could eventually move from over-the-counter trading to a major exchange like Nasdaq. That alone would unlock access for institutional investors and ETF inclusion, adding real support to the stock price.

I'm not saying Canopy is dead money, but if you're looking at the cannabis stock sector and want actual profitability with better positioning for what's coming next, Green Thumb looks like the stronger play right now. The balance sheet is cleaner, the earnings are real, and the upside scenarios from regulatory changes are more meaningful.